BMI1 and metastatic prostate carcinoma: COMMD3: BMI1 fusion expression and COMMD3 protein increases significantly in metastatic prostate cancer; COMMD3 activates oncogenes such as c-MYC, promotes prostate proliferation, migration and invasion; Increased COMMD3 expression is positively correlated with tumor recurrence and reduced survival (82).